Cinclus Pharma: FDA favors Voquezna market exclusivity - Redeye

Redeye comments on Phathom Pharmaceuticals’ recent announcement that the FDA has approved its Citizen Petition, confirming extended market exclusivity for Voquezna through May 2032. We view this as a positive development for Cinclus Pharma, as it strengthens the regulatory precedent for GAIN exclusivity, reduces competitive pressure from generics, and supports renewed investor confidence in linaprazan glurate’s commercial outlook.

Länk till analysen i sin helhet: https://www.redeye.se/research/1114580/cinclus-pharma-fda-favors-voquezna-market-exclusivity?utm_source=finwire&utm_medium=RSS